STC-004 / Eli Lilly - LARVOL DELTA

STC-004, a Novel Nav1.8 inhibitor, Produces an Analgesic Effect in a Human Model of Experimental Pain (NeuPSIG 2025) - No abstract available

CNS Disorders • Pain • NAV1

SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for the Non-Opioid Treatment of Pain (Businesswire) - P1 | N=76 | ACTRN12624000642583 | Sponsor: SiteOne Therapeutics | "Pharmacokinetic data showed rapid absorption with a half-life appropriate for once-daily oral dosing. Exposure was proportional and demonstrated low variability across the dose range. STC-004 was well-tolerated at all doses tested. Pharmacodynamic testing performed during the MAD cohorts using the Cold Pressor Test (CPT) model of experimental pain supported target engagement across the dose range tested. Statistically significant increases in the Pain Tolerance Threshold (PTT) were observed. These findings are consistent with target engagement of the human NaV1.8 channel at low, once-daily oral doses, demonstrating significant analgesic potential....'We are focused on rapidly advancing STC-004 into Phase 2 trials in the second half of this year'."

New P2 trial • P1 data • Pain • Peripheral Neuropathic Pain

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STC-004 (ANZCTR) - P1 | N=76 | Completed | Sponsor: SiteOne Therapeutics | Recruiting ➔ Completed

Trial completion • Neuralgia • Pain • Peripheral Neuropathic Pain

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STC-004 (ANZCTR) - P1 | N=76 | Recruiting | Sponsor: SiteOne Therapeutics | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2024

Enrollment open • Trial initiation date • Neuralgia • Pain • Peripheral Neuropathic Pain

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STC-004 (ANZCTR) - P1 | N=76 | Not yet recruiting | Sponsor: SiteOne Therapeutics

New P1 trial • Neuralgia • Pain • Peripheral Neuropathic Pain